drug

lorlatinib

Marketedupdated 2mo ago

by $PFE PFIZER INC

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 5 investigational indications.

indications

investigational

NSCLC

all catalysts(7)

approval · 7

News(0)

no news has mentioned this drug yet

brand

Lorbrena

generic

lorlatinib

MOA

12.1 Mechanism of Action Lorlatinib is a kinase inhibitor with in vitro activity against ALK and ROS1 as well as TYK1, FER, FPS, TRKA, TRKB, TRKC, FAK, FAK2, and ACK. Lorlatinib demonstrated in vitro activity against multiple mutant forms of the ALK enzyme, including some mutations detected in tumors at the time of disease progression on crizotinib and other ALK inhibitors. In mice subcutaneously implanted with tumors harboring EML4 fusions with either ALK variant 1 or ALK mutations, including the G1202R and I1171T mutations detected in tumors at the time of disease progression on ALK inhibitors, administration of lorlatinib resulted in antitumor activity. Lorlatinib also demonstrated anti-tumor activity and prolonged survival in mice implanted intracranially with EML4-ALK-driven tumor cell lines. The overall antitumor activity of lorlatinib in in vivo models was dose-dependent and correlated with inhibition of ALK phosphorylation.

indication

Non-Small Cell Lung Cancer

phase

marketed

lorlatinib

indications

all catalysts(7)

News(0)

Patent cliff

patents (8)

FDA exclusivities (2)

comments(0)

Report a data issue

🐶 often sniffed alongside

Trials studying lorlatinib